ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cannabidiol

Also written as “GWP42003-P”, “Cannabidiol Oral Solution” and “CBD”.

Its studies are mostly in Epilepsy · Lennox Gastaut Syndrome · Epilepsies, Myoclonic · Seizures · Spasms, Infantile, led by 16 companies.

Drug pageCannabidiol: every studyMany companies study it; this page follows only the 64 they lead. All 316 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 17, 201964 company-led studies, 8 open or runningNext primary completion: Aug 1, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals315 open or runningphase 4since Oct 17, 2019Oct 7, 2010Aug 1, 2027phase 4 · NCT05044819
INSYS Therapeuticsits history only50 open or runningphase 3since Dec 12, 2014Dec 12, 2014none ahead
Radius Pharmaceuticalsits history only50 open or runningphase 3since Jan 26, 2018Jul 22, 2016none ahead
Cardiol Therapeuticsits history only41 open or runningphase 3since Nov 2, 2020Nov 2, 2020none ahead
Pure Greenits history only40 open or runningphase 2since Sep 10, 2019Sep 10, 2019none ahead
Canopy Growthits history only30 open or runningphase 2since Aug 29, 2019Aug 29, 2019none ahead
Botanix Pharmaceuticalsits history only20 open or runningphase 2since Jun 19, 2018Jun 19, 2018none ahead
Stero Biotechsits history only20 open or runningphase 2since Mar 18, 2019Mar 18, 2019none ahead
Avecho Biotechnologyits history only11 open or runningphase 3since Apr 23, 2023Apr 23, 2023Sep 30, 2027phase 3 · NCT05840822
Bod Australiaits history only10 open or runningphase 2since Dec 20, 2021Dec 20, 2021none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Research UK and Benuvia Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jazz Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Oct 7, 2010.

  1. Nov 16, 20152 phase 2 studies in EpilepsyNCT02607904, NCT02607891
  2. Jun 9, 2016Named cannabidiolINNProposed as its International Nonproprietary Name in WHO's List 115 · before, GWP42003-P, GWP42003
  3. Nov 1, 20162 phase 3 studies in Spasms, InfantileNCT02953548, NCT02954887
  4. Feb 19, 2019Phase 3 study in Rett SyndromeNCT03848832 · 29 enrolled · United States, Italy, Spain and more
  5. Oct 17, 2019Phase 4 study in Lennox Gastaut SyndromeNCT04133480
  6. Jan 30, 2020Phase 3 study in Rett SyndromeNCT04252586 · 21 enrolled · United States, Australia, Canada and more
  7. May 27, 2020Phase 2 study in SchizophreniaNCT04421456 · 95 enrolled · United States, Poland, Serbia and more
  8. Jul 21, 2020Phase 3 study in EpilepsyNCT04485104 · 3 enrolled · United States, Italy, Spain
  9. Feb 4, 2021Phase 2 study in Autism Spectrum DisorderNCT04745026 · 103 enrolled · United States, Australia, Canada and more
  10. Aug 30, 2021Phase 4 study in Lennox Gastaut SyndromeNCT05044819 · 154 enrolled · United States
  11. Mar 11, 2022Phase 3 study in EpilepsyNCT05288283 · 3 enrolled · United States, Italy
  12. May 9, 2023Phase 4 study in SeizuresNCT05864846 · 79 enrolled · United States, Canada, Poland and more
  13. Nov 14, 2025Phase 1 study in SeizuresNCT07233239 · 100 planned · United States
  14. Jul 20, 20262 phase 3 studiesNCT07723976, NCT07723963
  15. Jul 22, 2026Phase 4 study in Lennox Gastaut SyndromeNCT07728097 · 40 planned · United States

Ahead

  1. Aug 1, 2027Primary completion: phase 4 study in Lennox Gastaut SyndromeNCT05044819
  2. Nov 29, 2027Primary completion: phase 1 study in SeizuresNCT07233239
  3. Aug 1, 2028Primary completion: phase 3 study in Myoclonic Epilepsy, JuvenileNCT07723963
  4. Dec 28, 2028Primary completion: phase 4 study in Lennox Gastaut SyndromeNCT07728097

TargetBeta

CNR1 →read by rule
“Cannabinoid CB1 receptor negative allosteric modulator”ChEMBL 37, by rule

Other programs on CNR1

ProgramCompanyFurthest phaseStudies
RimonabantruleSanofiphase 339
DronabinolruleJazz Pharmaceuticalsphase 320
CRB-913rulecorbus-pharmaceuticals-incphase 11

Studies

All 31 Jazz Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07728097Lennox Gastaut Syndrome · United States4Not yet recruitingDec 28, 202840
NCT07723976Developmental and Epileptic Encephalopathy (DEE) · United States, Australia, Hungary and more3RecruitingSep 4, 2029120
NCT07723963Myoclonic Epilepsy, Juvenile · United States3RecruitingAug 1, 2028260
NCT07233239Seizures · United States1RecruitingNov 29, 2027100
NCT05864846Seizures · United States, Canada, Poland and more4CompletedApr 6, 202679
NCT05288283Epilepsy · United States, Italy3TerminatedSep 28, 20233
NCT05044819Lennox Gastaut Syndrome · United States4Active, not recruitingAug 1, 2027154
NCT04745026Autism Spectrum Disorder · United States, Australia, Canada and more2CompletedDec 21, 2023103
NCT04485104Epilepsy · United States, Italy, Spain3TerminatedJan 28, 20253
NCT04421456Schizophrenia · United States, Poland, Serbia and more2TerminatedMar 16, 202295
NCT04252586Rett Syndrome · United States, Australia, Canada and more3TerminatedJun 9, 202121
NCT04133480Lennox Gastaut Syndrome4WithdrawnDec 20210
NCT03848832Rett Syndrome · United States, Italy, Spain and more3TerminatedJan 21, 202129
NCT02954887Spasms, Infantile · United States, Poland3CompletedJun 13, 20199
NCT02953548Spasms, Infantile · United States, Poland3CompletedMay 7, 20189
NCT02607904Epilepsy · Netherlands, Spain, Sweden2CompletedMay 27, 201930
NCT02607891Epilepsy · Netherlands, Spain, Sweden2CompletedSep 11, 201835
NCT02565108Epilepsy · Spain, United Kingdom2CompletedJul 21, 201620
NCT02564952Epilepsy · Spain, United Kingdom2CompletedJun 7, 201718
NCT02544763Tuberous Sclerosis · United States, Australia, Netherlands and more3CompletedJan 22, 2019224
NCT02544750Tuberous Sclerosis · United States3CompletedJun 11, 2021199
NCT02224703Epilepsy · United States, Australia, Israel and more3CompletedApr 9, 2018199
NCT02224690Epilepsy · United States, Netherlands, Poland3CompletedMar 18, 2016171
NCT02224573Epilepsy3CompletedSep 24, 2020681
NCT02224560Epilepsy · United States, France, Spain and more3CompletedMay 19, 2016225
NCT02091375Epilepsy · United States, France, Poland and more3CompletedNov 26, 2015120
NCT02091206Epilepsy · United States, United Kingdom2CompletedMar 9, 201534
NCT02006628Schizophrenia · Poland, Romania, United Kingdom2CompletedJan 8, 201588
NCT01562314Colitis, Ulcerative · United Kingdom2CompletedAug 5, 201460
NCT01284634Fatty Liver · United Kingdom2CompletedJul 13, 201225
NCT01217112Dyslipidemias · United Kingdom2CompletedMay 201262

How it is read

Names in the registry

  • “GWP42003-P”, 17 entries
  • “Cannabidiol Oral Solution”, 10 entries
  • “Cannabidiol”, 7 entries
  • “CBD”, 5 entries
  • “GWP42003”, 4 entries

Codes read as this program: JZP926.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.